Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Vedanta Biosciences

News headline image
Vedanta Biosciences Showcases Innovative Work on its Microbiome-based Therapeutics at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2026 Global Congress
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences to Present at Upcoming Investor Conferences
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences to Host Investor Meetings at the Leerink Partners 2024 Global Biopharma Conference
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences’ Key Microbiome Patents Fully Upheld in Three European Opposition Proceedings
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences to Host Investor Meetings at the Wells Fargo Virtual Private Biotech Symposium
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences Presents Progress from Two Defined Bacterial Consortia, VE303 for the Prevention of C. difficile and VE707 for the Prevention of Gram-Negative Infections, at IDWeek 2023
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences to Participate at Upcoming Investor Conferences
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences to Present at Upcoming Investor Conferences
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences to Present at the 9th International Human Microbiome Consortium Congress
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences to Present at Upcoming Investor Conferences
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting
From Vedanta Biosciences
Via Business Wire
Tickers PRTC
News headline image
Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences to Present at Chardan’s 2022 Metagenomics and Microbiome Medicines Summit
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)
From Vedanta Biosciences
Via Business Wire
Tickers PRTC
News headline image
Vedanta Biosciences to Present at the SVB Leerink Biopharma Private Company Connect Event
From Vedanta Biosciences
Via Business Wire
News headline image
Vedanta Biosciences to Present at the 2021 Jefferies Virtual Microbiome-Based Therapeutics Summit
From Vedanta Biosciences
Via Business Wire
Tickers PRTC
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.